Delve into the neuroprotective role of the Endocannabinoid System (ECS) in the brain, with particular emphasis on CB1 and CB2 cannabinoid receptors. This comprehensive review covers the ECS’s crucial role in neuronal protection against trauma, ischemia, neuroinflammation, and neurodegeneration. Additionally, learn about the potential therapeutic implications of various endogenous neuroprotective compounds that interact with the ECS.
A phase I double-blind placebo-controlled clinical trial examined the effects of a 10:1 CBD/THC sublingual spray in improving glycemic control and lipid profiles in patients with Type II Diabetes. The study involved 50 patients, 25 of whom were given a 200 mg/20 mg CBD/Δ9-THC sublingual spray twice daily for eight weeks, while the other 25 were given a placebo. The study found that the active treatment arm showed significant improvements in various biomarkers related to cardiovascular health and glucose metabolism. The results suggest that adjunctive treatment with sublingual CBD/Δ9-THC can improve glycemic control and lipid profiles in patients with Type II Diabetes.